Agios Pharmaceuticals, Inc. (AGIO) – What Are Analysts Thinking About This Stock?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has earned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $41.50.

AGIO has been the subject of several research reports. TD Cowen raised shares of Agios Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 24th. Truist Financial dropped their price objective on shares of Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating on the stock in a research note on Wednesday, October 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday, September 21st. Bank of America raised their target price on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Finally, Royal Bank Of Canada raised their target price on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a report on Tuesday, July 7th.

Insider Activity at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 30,000 shares of the stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total transaction of $914,400.00. Following the sale, the insider directly owned 54,645 shares in the company, valued at approximately $1,665,579.60. This represents a 35.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGIO. Assenagon Asset Management S.A. lifted its stake in Agios Pharmaceuticals by 1,714.6% in the third quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock valued at $62,723,000 after buying an additional 1,782,457 shares during the last quarter. Tidal Investments LLC grew its position in shares of Agios Pharmaceuticals by 12.0% during the second quarter. Tidal Investments LLC now owns 16,100 shares of the biopharmaceutical company’s stock worth $597,000 after acquiring an additional 1,724 shares during the last quarter. Engineers Gate Manager LP grew its position in shares of Agios Pharmaceuticals by 86.4% during the second quarter. Engineers Gate Manager LP now owns 53,912 shares of the biopharmaceutical company’s stock worth $2,001,000 after acquiring an additional 24,992 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of Agios Pharmaceuticals during the second quarter worth about $47,000. Finally, Squarepoint Ops LLC grew its position in shares of Agios Pharmaceuticals by 53.7% during the second quarter. Squarepoint Ops LLC now owns 321,138 shares of the biopharmaceutical company’s stock worth $11,917,000 after acquiring an additional 112,250 shares during the last quarter.

Agios Pharmaceuticals Price Performance

Shares of AGIO opened at $31.32 on Friday. The business’s fifty day moving average price is $33.08 and its 200 day moving average price is $32.69. Agios Pharmaceuticals has a 12-month low of $22.24 and a 12-month high of $46.00. The stock has a market capitalization of $1.87 billion, a PE ratio of -4.47 and a beta of 0.63.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. The business had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. As a group, research analysts anticipate that Agios Pharmaceuticals will post -5.83 earnings per share for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases. Based in Cambridge, Massachusetts, the company specializes in cellular metabolism and the development of therapies designed to address underlying disease biology rather than only treating symptoms.

Agios’ lead commercial product is Pyrukynd (mitapivat), an oral pyruvate kinase activator approved for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.